Prognosis of rectal carcinoma after multimodal treatment: YPTNM classification and tumor regression grading are essential

Anticancer Research

Volumn 33, Issue 2, 2013, Pages 559-566

  Hermanek, Paul ^a,b   Merkel, Susanne ^a   Hohenberger, Werner ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Histological regression grade; Neoadjuvant radiochemotherapy; Rectal carcinoma; YpTNM classification

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMORADIOTHERAPY; ADOLESCENT; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; FEMALE; HISTOPATHOLOGY; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RADICAL RESECTION; RECTUM CARCINOMA;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; CHEMORADIOTHERAPY; DIGESTIVE SYSTEM SURGICAL PROCEDURES; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM GRADING; NEOPLASM STAGING; PROGNOSIS; RECTAL NEOPLASMS;

EID: 84875887027     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Compton CC, Fielding LP, Burgart LJ, Conley B, Cooper HS, Hamilton SR, Hammond ME, Henson DE, Hutter RV, Nagle RB, Nielsen ML, Sargent DJ, Taylor CR, Welton M and Willett C: Prognostic factors in colorectal cancer: College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 124(7): 979-994, 2000.
2. Gosens MJ, Klaassen RA, Tan-Go I, Rutten HJ, Martijn H, van den Brule AJ, Nieuwenhuijzen GA, van Krieken JH and Nagtegaal ID: Circumferential margin involvement is the crucial prognostic factor after multimodality treatment in patients with locally advanced rectal carcinoma. Clin Cancer Res 13(22 Pt 1): 6617-6623, 2007.
3. Nagtegaal ID and Quirke P: What is the role of the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 26(2): 303-312, 2008.
4. Quirke P, Steele R, Monson J, Grieve R, Khanna S, Couture J, O'Callaghan C, Myint AS, Bessell E, Thompson LC, Parmar M, Stephens RJ and Sebag-Montefiore D: Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: A prospective study using data from the MRC CR07 and NCIC-CTG C016 randomised clinical trial. Lancet 373(9666): 821-828, 2009.
5. Röel C, Arnold D and Liersch T: Rectal cancer. In: Gastrointestinal Oncology. A Practical Guide. Blanke CD, Röel C and Talamonti M (eds.). Dordrecht: Springer, pp. 379-422, 2011.
6. UICC: TNM Supplement. A commentary on Uniform Use. 4th ed. Wittekind Ch, Compton CC, Brierley J and Sobin LH (eds.). New York: John Wiley & Sons, 2012.
7. Röel C, Martus P, Papadopoulos T, Füesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R and Wittekind C: Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23(34): 8688-8696, 2005.
8. UICC: TNM Supplement. A Commentary on Uniform use. 3rd ed. Wittekind Ch, Greene FL, Henson DE, Hutter RVP and Sobin LH (eds.). New York: John Wiley & Sons, 2003.
9. UICC: TNM Classification of Malignant Tumours. 7th ed. Sobin LH, Gospodarowicz MK and Wittekind Ch (eds.). New York: John Wiley & Sons, 2009.
10. Dworak O, Keilholz L and Hoffmann A: Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorect Dis 12(1): 19-23, 1997.
11. Wittekind Ch and Tannapfel A: Regression grading for rectal carcinoma after preoperative radiochemotherapy. Pathologe 24(1): 61-65, 2003 (in German).
12. Glynne-Jones R, Mawdsley S and Novell R: The clinical significance of the circumferential resection margin following preoperative pelvic chemoradiation in rectal cancer: why we need a common language. Colorectal Dis 8(9): 800-807, 2006.
13. Nagtegaal ID, van de Velde CJH, Marijnen CAM, van Krieken JHJM and Quirke P: Low rectal cancer: A call for a change of approach in abdominoperineal resection. J Clin Oncol 23(36): 9257-9264, 2005.
14. Quirke P and Morris E: Reporting colorectal cancer. Histopathology 50(1): 103-112, 2007.
15. Sauer R, Becker H, Hohenberger W, Röel C, Wittekind C, Fietkau R, Martus P, Tschmelitsch J, Hager E, Hess CF, Karstens JH, Liersch T, Schmidberger H, Raab R; German Rectal Cancer Study Group: Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 351(17): 1731-1740, 2004.
16. Harrell FE, Lee KL and Mark DB: Multivariable prognostic models: issues in developing models, evaluating assumption and adequacy, and measuring and reducing errors. Statistics Med 15(4): 361-387, 1996.
17. Association of Directors of Anatomic and Surgical Pathology (Jass JR, O'Brien MJ, Riddell RH and Snover DC): Recommendations for the reporting of surgically resected specimens of colorectal carcinoma. Am J Clin Pathol 129(1): 13-23, 2008.
18. Ryan R, Gibbons D, Hyland JMP, Treanor D, White A, Mulcahy HE, O'Donoghue DP, Moriarty M, Fennelly D and Sheahan K: Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology 47(2): 141-146, 2005.
19. Valentini V, Aristei C, Glimelius B, Minsky BD, Beets-Tan R, Borras JM, Haustermans K, Maingon P, Overgaard J, Pahlman L, Quirke P, Schmoll HJ, Sebag-Montefiore D, Taylor I, Van Cutsem E, Van de Velde C, Cellini N, Latini P; Scientific Committee: Multidisciplinary rectal cancer management: Second European Rectal Cancer Consensus Conference (EURECACC2). Radiother Oncol 92(2): 148-163, 2009.
20. College of American Pathologists (CAP) (Washington K, Berlin J, Branton P, Burgart LJ, Carter DK, Fitzgibbons P, Frankel WL, Halling KC, Jessup J, Kakar S, Minsky B, Nakhleh R and Comptin CC): Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum 3.1.0.0. Available at: http://www.cap.org/apps/docs/committees/cancer/cancer-protocols/ 2011/Colon-11protocol.pdf Last accessed November 20, 2012.
21. National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Rectal Cancer. Version 2.2012. Available at: http://www.tri-kobe.org/nccn/guideline/colorectal/english/rectal. pdf Last accessed November 20, 2012.
22. Caricato M, Ausania F, De Dominicis E, Vincenzi B, Rabitti C, Tonini G, Cellini F and Coppola R: Tumor regression in mesorectal lymph nodes after neoadjuvant chemoradiation for rectal cancer. Eur J Surg Oncol 33(6): 724-728, 2007.
23. Read TE, Andujar JE, Caushaj PF, Johnston DR, Dietz DW, Myerson RJ, Fleshman JW, Birnbaum EH, Mutch MG and Kodner IJ: Neoadjuvant therapy for rectal cancer: Histologic response of the primary tumor predicts nodal status. Dis Colon Rectum 47(6): 825-831, 2004.
24. Hughes R, Glynne-Jones R, Grainger J, Richman P, Makris A, Harrison M, Ashford R, Harrison RA, Livingstone JI, McDonald PJ, Meyrick Thomas J, Mitchell IC, Northover JM, Phillips R, Wallace M, Windsor A and Novell JR: Can pathological complete response in the primary tumor following pre-operative pelvic chemoradiotherapy for T3-T4 rectal cancer predict for sterilisation of pelvic lymph nodes, a low risk of local recurrence and the appropriateness of local excision? Int J Colorectal Dis 21(1): 11-17, 2006.
25. Kim D-W, Kim DY, Kim TH, Jung KH, Chang HJ, Sohn DK, Lim SB, Choi HS, Jeong SY and Park JG: Is T classification still correlated with lymph node status after preoperative chemoradiotherapy for rectal cancer? Cancer 106(8): 1694-1700, 2006.
26. Mignanelli ED, de Campos-Lobato LF, Stocchi L, Lavery IC, and Dietz DW. Downstaging after chemoradiotherapy for locally advanced rectal cancer: Is there more (tumor) than meets the eye? Dis Colon Rectum 53(3): 251-256, 2010.
27. Yeo SG, Kim DY, Kim TH, Chang HJ, Oh JH, Park W, Choi DH, Nam H, Kim JS, Cho MJ, Kim JH, Park JH, Kang MK, Koom WS, Kim JS, Nam TK, Chie EK, Kim JS and Lee KJ: Pathologic complete response of primary tumor following preoperative chemoradiotherapy for locally advanced rectal cancer. Ann Surg 252(6): 998-1004, 2010.
28. Shia J, Guillem JG, Moore HG, Tickoo SK, Qin J, Ruo L, Suriawinata A, Paty PB, Minsky BD, Weiser MR, Temple LK, Wong WD and Klimstra DS: Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome. Am J Surg Pathol 28(2): 215-223, 2004.
29. Prall F, Wölke M, Klautke G, Schiffmann L, Fietkau R and Barten M. Tumour regression and mesorectal lymph node changes after intensified neoadjuvant chemoradiation for carcinoma of the rectum. APMIS 114(3): 201-210, 2006.
30. Rubbia-Brandt L, Giostra E, Brezault C, Roth AD, Andres A, Audard V, Sartoretti P, Dousset B, Majno PE, Soubrane O, Chaussade S, Mentha G and Terris B: Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neoadjuvant chemotherapy followed by liver surgery. Ann Oncol 18(2): 299-305, 2007.
31. Blazer DG 3rd, Kishi Y, Maru DM, Kopetz S, Chun YS, Overman MJ, Fogelman D, Eng C, Chang DZ, Wang H, Zorzi D, Ribero D, Ellis LM, Glover KY, Wolff RA, Curley SA, Abdalla EK and Vauthey JN: Pathologic response to preoperative chemotherapy: A new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 25(33): 5344-5351, 2008.
32. Maru DM, Kopetz S, Boonsirikamchai P, Agarwal A, Chun YS, Wang H, Abdalla EK, Kaur H, Charnsangavej C, Vauthey JN and Loyer EM: Tumor thickness at the tumor-normal interface: A novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol 34(9): 1287-1294, 2010.
33. Smith FM, Waldron D and Winter DC: Rectum-conserving surgery in the era of chemoradiotherapy. Br J Surg 97(12): 1752-1764, 2010.
34. Berger C, de Muret A, Garaud P, Chapet S, Bourlier P, Reynaud-Bougnoux A, Dorval E, de Calan L, Huten N, le Floch O and Calais G: Preoperative radiotherapy (RT) for rectal cancer: Predictive factors of tumor downstaging and residual tumor cell density (RCTD): Prognostic implications. Int J Radiat Oncol Biol Phys 37(3): 619-627, 1997.
35. Gavioli M, Luppi G, Losi L, Bertolini F, Santantonio M, Falchi AM, D'Amico R, Conte PF and Natalini G: Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer. Dis Colon Rectum 48(10): 1851-1857, 2005.
36. Guillem JG, Chessin DB, Cohen AM, Shia J, Mazumdar M, Enker W, Paty PB, Weiser MR, Klimstra D, Saltz L, Minsky BD and Wong WD: Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg 241(5): 929-938, 2005.
37. Vecchio FM, Valentini V, Minsky BD, Padula GDA, Venkatraman ES, Balducci M, Micciché F, Ricci R, Morganti AG, Gambacorta MA, Maurizi F and Coco C: The relationship of pathologic tumor regression grade (TRG) and outcomes after preoperative therapy in rectal cancer. Int J Radiat Oncol Biol Phys 62(3): 752-760, 2005.
38. Rullier A, Laurent C, Capdepont M, Vendrely V, Bioulac-Sage P and Rullier E: Impact of tumor response on survival after radiochemotherapy in locally advanced rectal carcinoma. Am J Surg Pathol 34(4): 562-568, 2010.
39. Beddy D, Hyland JM, Winter DC, Lim C, White A, Moriarty M, Armstrong J, Fennelly D, Gibbons D and Sheahan K: A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy. Ann Surg Oncol 15(12): 3471-3477, 2008.
40. Bozourene H, Bosman FT, Seelentag W, Matter M and Coucke P: Importance of tumor regression assessment in predicting the outcome in patients with locally rectal carcinoma who are treated with preoperative radiotherapy. Cancer 94(4): 1121-1130, 2002.
41. Wheeler JM, Warren BF, Mortensen NJ, Ekanyaka N, Kulacoglu H, Jones AC, George BD and Kettlewell MGW: Quantification of histologic regression of rectal cancer after irradiation: A proposal for a modified staging system. Dis Colon Rectum 45(8): 1051-1056, 2002.
42. Barbaro B, Fiorucci C, Tebala C, Valentini V, Gambacorta MA, Vecchio FM, Rizzo G, Coco C, Crucitti A, Ratto C and Bonomo L: Locally advanced rectal cancer: MR imaging in prediction of response after preoperative chemotherapy and radiation therapy. Radiology 250(3): 730-739, 2009.
43. Kim SH, Lee JM, Park HS, Eun HW, Han JK and Choi BI: Accuracy of MRI for predicting the circumferential resection margin, mesorectal fascia invasion, and tumor response to neoadjuvant chemoradiotherapy for locally advanced rectal cancer. J Magn Reson Imaging 29(5): 1093-1101, 2009.
44. Patel UB, Taylor F, Blomqvist L, George C, Evans H, Tekkis P, Quirke P, Sebag-Montefiore D, Moran B, Heald R, Guthrie A, Bees N, Swift I, Pennert K and Brown G: Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol 29(28): 3753-3760, 2011.
45. Shihab OC, Taylor F, Salerno G, Heald RJ, Quirke P, Moran BJ and Brown G: MRI predictive factors for long-term outcomes of low rectal tumours. Ann Surg Oncol 18(12): 3278-3284, 2011.
46. Lambrecht M, Vandecaveye V, De Keyzer F, Roels S, Penninckx F, Van Cutsem E, Filip C and Haustermans K: Value of diffusionweighted magnetic resonance-imaging for prediction and early assessment of response to neoadjuvant radiochemotherapy in rectal cancer: Preliminary results. Int J Radiat Oncol Biol Phys 82(2): 863-870, 2012.
47. Janssen MH, Öllers MC, van Stiphout RGPM, Riedl RG, van den Bogaard J, Buijsen J, Lambin P and Lammering G: PETbased treatment response evaluation in rectal cancer: Prediction and validation. Int J Radiat Oncol Biol Phys 82(2): 871-876, 2012.
48. Valentini V and Cellini F: Management of local rectal cancer: Evidence, controversies and future perspectives in radiotherapy. Colorectal Cancer 1(2): 163-177, 2012.